GD3
Chr XARGraves disease, susceptibility to, X-linked
Also known as: GD3
Primary Disease Associations & Inheritance
Gaucher disease, type IIIMIM #231000
AR
0
ClinVar variants
0
Pathogenic / LP
—
pLI score
1
Active trials
Clinical Summary— GD3
💊
Clinical Trials
1 active or recruiting trial — potential therapeutic options may be available
Some data sources returned errors (2)
ensembl: Error: Ensembl fetch failed: 400 for https://rest.ensembl.org/lookup/symbol/homo_sapiens/GD3?content-type=application/json&expand=1
gnomad: Error: Gene not found
Population Genetics & Constraint
Constraint data not available from gnomAD.
ClinVar Variant Classifications
0 submitted variants in ClinVar
Protein Context — Lollipop Plot
GD3 · protein map & ClinVar variants
Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.
OMIM — Genotype-Phenotype Relationships
1 OMIM entry
GAUCHER DISEASE, TYPE III; GD3
MIM #231000 · #
Autosomal recessive
External Resources
Links to major genomics databases and tools
Variant Interpretation
Population Databases
Gene Resources
Expert Curation
📖
Open GeneReview ↗GeneReview available — GD3
Authoritative clinical overview · NCBI Bookshelf · Recommended first read
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
Diagnosing neuronopathic Gaucher disease: New considerations and challenges in assigning Gaucher phenotypes.
Daykin EC et al.·Mol Genet Metab
2021Review
Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1.
Mabe NW et al.·Nat Cancer
2022
Clinical and preclinical insights into high-dose ambroxol therapy for Gaucher disease type 2 and 3: A comprehensive systematic review.
den Hollander B et al.·Mol Genet Metab
2024Review
Ganglioside Profiling Uncovers Distinct Patterns in High-Risk Neuroblastoma.
Paret C et al.·Int J Mol Sci
2025
Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer.
Shao C et al.·Ann N Y Acad Sci
2022Review
GD2 in Breast Cancer: A Potential Biomarker and Therapeutic Target.
Mokbel K·Cancer Genomics Proteomics
2024Review
EDF1 accelerates ganglioside GD3 accumulation to boost CD52-mediated CD8(+) T cell dysfunction in neuroblastoma.
Li D et al.·J Exp Clin Cancer Res
2025
Top 10 resultsSearch PubMed ↗
Recent Gene-Specific Literature
Gene in title · MEDLINE · newest first
GM1 and GD3 Gangliosides Attenuate Diisopropylfluorophosphate-Induced NGF-TrkA and BDNF-TrkB Signaling Dysfunction.
Itokazu Y et al.·ACS Chem Neurosci
2026🔓 Open Access
Reactivity of the Asymmetric Wells-Dawson Ion: Lanthanide-Containing 34-Tungsto-2-Phosphates [Ln(P(H4)W17O61)2]19- (Ln = La3+, Ce3+, Eu3+, Gd3+, Yb3+, Lu3+, Y3+).
Elcheikh Mahmoud M et al.·Inorg Chem
2026🔓 Open Access
Gd3+ engineered Co-Mn-Mg spinel nanoferrites for multifunctional theranostics: magnetic hyperthermia, antioxidant hepatoprotection, and antibacterial activity.
Elansary M et al.·RSC Adv
2025🔓 Open AccessFunctional
Dynamic tracking of GD3 to GD2 gangliosides in T lymphoblasts via nuclear magnetic resonance spectroscopy.
Salinas-Marín R et al.·Glycobiology
2025
Chemoenzymatically Synthesized O-Acetylated GD3 Gangliosides to Examine Viral Receptor Specificities in a Cellular Context.
Zhang Z et al.·Angew Chem Int Ed Engl
2026🔓 Open Access
Top 5 resultsSearch Europe PMC ↗
Clinical Trials
Active and recruiting trials from ClinicalTrials.gov
External Resources
Links to major genomics databases and tools